Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Medincell's Free Cash Flow for the
six
months ended in Mar. 2026 was €-9.75 Mil. Medincell's Revenue for the
six
months ended in Mar. 2026 was €7.91 Mil. Therefore, Medincell's FCF Margin % for the quarter that ended in Mar. 2026 was -123.27%.
The historical rank and industry rank for Medincell's FCF Margin % or its related term are showing as below:
LTS:0ACH'
s FCF Margin % Range Over the Past 10 Years
Min: -1156.34 Med: -150.7 Max: 69.71
Current: -130.13
During the past 11 years, the highest FCF Margin % of Medincell was 69.71%. The lowest was -1156.34%. And the median was -150.70%.
LTS:0ACH's FCF Margin % is ranked worse than 56.32% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs LTS:0ACH: -130.13
Medincell FCF Margin % Related Terms
Medincell FCF Margin % Historical Data
* Premium members only.
The historical data trend for Medincell's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0ACH vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Medincell's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medincell FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medincell's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Medincell's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medincell (LTS:0ACH) has a FCF Margin % of -123.27% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medincell and its competitors. According to the industry distribution chart, Medincell ranks #535 out of 950 companies in the Biotechnology industry, placing it in the top 56.3%.
Is Medincell's FCF Margin % too high?
Medincell's current FCF Margin % is -123.27%. Based on the distribution chart, Medincell ranks #535 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Medincell has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medincell's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medincell ranks #535 out of 950 companies for FCF Margin %. This places Medincell in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medincell and its competitors. Medincell's current FCF Margin % is -123.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Based on GuruFocus' analysis, Medincell (LTS:0ACH) is currently considered Modestly Overvalued. The stock's GF Value™ is €21.95, compared to a current price of €26.88 — trading 22.5% above its estimated fair value. The current FCF Margin % is -123.27%. Medincell's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Medincell (LTS:0ACH), the current FCF Margin % is -123.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medincell (LTS:0ACH) Overvalued in 2026?
Based on GuruFocus' analysis, Medincell stock appears to be overvalued.
The current stock price of €26.88 is trading 22.5% above its estimated GF Value™ of €21.95.
GuruFocus considers Medincell to be Modestly Overvalued.
Key valuation signals for LTS:0ACH:
FCF Margin %: -123.27%
GF Value™: €21.95 vs. price of €26.88 (22.5% above fair value)
No single metric tells the full story. See the LTS:0ACH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
78GF Score
Get the complete analysis for LTS:0ACH
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0ACH has been successfully added to your 
